Moreover, the relative abundance of f-Lactobacillus was enhanced by 5% AFG, and it has been reported that oral Lactobacillus tablets decreased the levels of GOT and GPT in patients with NAFLD in two double-blind randomized clinical trials [28,29]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.